PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc., filing under the ticker FSII, submitted an 8-K current report to the SEC on June 5, 2023, disclosing a material corporate development. The company entered public markets through a de-SPAC combination with FS Development Corp. II, a blank-check vehicle sponsored by FS Development Holdings II, LLC, an affiliate of Foresite Capital, which priced its IPO in 2021. Pardes Biosciences operates in the clinical-stage biopharmaceutical sector, with a pipeline centered on antiviral therapeutics. The June 2023 filing reflects the company's ongoing disclosure obligations as a post-combination public entity. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time data on this and hundreds of other SPAC transactions.